Journal of Oncology Pharmacy Practice最新文献

{"title":"Development of a machine learning-based risk warning model for potentially inappropriate medication use among older patients in a hematology service.","authors":"Aslınur Albayrak, Başak Firdevs Dilara Tokgöz, Demircan Özbalcı","doi":"10.1177/10781552261499304","DOIUrl":"https://doi.org/10.1177/10781552261499304","url":null,"abstract":"<p><p>IntroductionOlder hematology patients often have multiple comorbidities and receive complex medication therapies; this can increase the risk of potentially inappropriate medication (PIM) use. A machine learning model could potentially serve as an automated screening and warning tool to facilitate the identification of PIM and support timely medication review in these patients. The aim of this study is to develop machine learning-based model that provide warnings regarding PIMs use in elderly patients hospitalized in the hematology service.MethodsThis retrospective pilot study was conducted on patients over 65 years of age who were admitted to the hematology service of a university hospital in Türkiye between 2018 and 2020. PIMs were determined according to the American Geriatrics Association's 2023 Beers Criteria. Python (v3.12.7) was used for data analysis in this study. The stratified 5-fold cross-validation method was used. To estimate PIM, seven different classification algorithms were used. Model performance was compared using accuracy, precision, recall, F1 score, receiver operating characteristics (ROC) curve, and area under the curve (AUC), brier score evaluation parameters.ResultsThis study included 190 patients. 45.8% of patients had PIM. The logistic regression model demonstrated the highest performance with 0.87 accuracy, 0.83 recall, 0.86 F1 score, and 0.91 AUC.ConclusionThe logistic regression model was determined to be the best-performing model. The developed patient-based automated screening model is promising and can be considered a reliable early warning mechanism for clinical pharmacists and physicians.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261499304"},"PeriodicalIF":1.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author response to the Letter to the Editor: \"Model informed precision dosing for most accurate busulfan therapeutic drug monitoring\".","authors":"Sandra García-Contreras, María Remedios Marqués-Miñana, Virginia Bosó-Ribelles, Carolina Fuentes-Socorro, Paloma Escobar-Cava, Javier García-Pellicer, José Luis Poveda-Andrés","doi":"10.1177/10781552261499517","DOIUrl":"https://doi.org/10.1177/10781552261499517","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261499517"},"PeriodicalIF":1.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of comedication on survival and toxicity in patients treated with systemic therapy for unresectable hepatocellular carcinoma.","authors":"M Boulin, M Bellini, S Burlet, T Fevre, M Albert, P Pistre, C Lepage, M Latournerie, S Manfredi","doi":"10.1177/10781552261497955","DOIUrl":"https://doi.org/10.1177/10781552261497955","url":null,"abstract":"<p><p>IntroductionThis study aims to evaluate the association between concomitant medication, survival and toxicity in patients with unresectable hepatocellular carcinoma (uHCC) treated with systemic therapy.MethodsAll uHCC patients treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab in our center were included. Endpoints were progression-free survival (PFS), HCC-specific survival, grade ≥4 adverse events (AE) and treatment-related discontinuation.ResultsOne hundred and five patients were included, 88 treated with atezolizumab plus bevacizumab and 17 with durvalumab plus tremelimumab. The most common prescribed concomitant medication was cardiovascular drugs (62%). Median PFS and HCC-specific survival were 6.0 (95% CI 4.0-12.0) and 19.0 months (95% CI 14.0-25.0) for atezolizumab plus bevacizumab versus 5.0 (95% CI 2.0-19.0) and 17.0 months (95% CI 7.0-21.0) for durvalumab plus tremelimumab, respectively. Five (6%) and 4 (24%) patients presented at least one grade ≥4 AE, respectively (P = 0.04). Grade ≥4 AE and treatment-related discontinuation were more frequent in patients with at least one psycholeptic or psychoanaleptic drug (17% vs 3%, P = 0.03 and 12% vs 2%, P = 0.03).ConclusionsIn this real-world cohort of patients with uHCC, baseline concomitant medication was not significantly associated with PFS or HCC-specific survival. Psycholeptic or psychoanaleptic drug intake was associated with grade ≥4 AE and treatment-related discontinuation, but these findings should be considered hypothesis-generating because of the retrospective design, small sample size and potential confounding.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261497955"},"PeriodicalIF":1.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Development and internal validation of a clinical prediction model for 90-day clinically significant medication-related harm in adults initiating oral anticancer therapy: A multicenter prospective cohort study\".","authors":"Huseyin Gencer","doi":"10.1177/10781552261498426","DOIUrl":"https://doi.org/10.1177/10781552261498426","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498426"},"PeriodicalIF":1.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication safety in pediatric oncology survivorship: Polypharmacy, high-risk medications, drug interactions, adherence, and caregiver education.","authors":"Ayodeji Otufowora, Adedoyin Okusanya, Aderonke Okusanya","doi":"10.1177/10781552261498054","DOIUrl":"https://doi.org/10.1177/10781552261498054","url":null,"abstract":"<p><p>ObjectiveMedication safety is an underdeveloped dimension of pediatric oncology survivorship despite persistent medication exposure after cancer therapy. This review synthesizes evidence on chronic medication burden and polypharmacy, high-risk medications, drug interactions, adherence and medication reconciliation, caregiver and survivor education, household medication safety, and systems-level strategies.Data SourcesA focused narrative review was conducted using targeted searches of PubMed-indexed literature and iterative reference-list and citation review through August 2026. Priority was given to survivor-specific cohort studies, systematic reviews, and current survivorship guidance. When direct survivorship evidence was limited, selected broader literature on multimorbidity, drug-supplement interactions, and pediatric-to-adult transition was included to inform potentially transferable medication-safety mechanisms and care processes.Data SummarySurvivor-specific evidence demonstrates persistent medication use, polypharmacy in selected high-risk groups, increased early post-therapy opioid prescribing and claims-based indicators of potential opioid misuse, greater psychoactive medication use than in sibling controls, complementary medicine use with potential drug interactions, and cost-related nonadherence. Broader multimorbidity and transition literature informs comprehensive interaction review, medication reconciliation, and structured transfer of medication-management responsibility, while pediatric oncology studies identify home medication errors, caregiver medication-management challenges, and potential roles for pharmacists.ConclusionsMedication safety should be approached as a longitudinal, exposure-aware component of survivorship care that balances treatment of late effects with prevention of medication-related harm. Major evidence gaps include survivor-specific data on adverse drug events, clinically consequential interactions, potentially inappropriate prescribing, deprescribing, pharmacist-led interventions, and medication safety during transition to adult care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498054"},"PeriodicalIF":1.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, implementation, and evaluation of a mentorship program within hematology/oncology pharmacy association (HOPA) - a professional oncology pharmacy organization.","authors":"Eno Inyang, Morgan P Randolph, Mark N Sorial, Kristin Adler, Mollie Beck, Bryna Delman Ewachiw, Rebecca Fahrenbruch, J Andrew Orr-Skirvin, Sara A Scott, Donald C Moore","doi":"10.1177/10781552261498404","DOIUrl":"https://doi.org/10.1177/10781552261498404","url":null,"abstract":"<p><p>BackgroundFormal mentorship programs are important for the pharmacy profession. In 2019, the Hematology/Oncology Pharmacy Association (HOPA) launched their Mentorship Program aimed at pairing early-career pharmacists with senior HOPA members. Following an initial pilot program, the program was further expanded with supportive infrastructure as an annual offering from HOPA to eligible members.ObjectiveTo assess the impact of the HOPA Mentorship Program on involvement in the organization and to evaluate changes in self-reported professional and leadership perceptions following participation in the Mentorship Program.MethodsWe retrospectively analyzed HOPA-level membership data of participants going through the Mentorship Program to assess their involvement in HOPA following program participation in domains including committee membership, committee leadership, conference attendance, and advocacy event participation. Mentees in the program also completed pre- and post-program surveys as part of their participation in the program. Median composite pre-and post-program survey responses were compared to assess changes in self-reported professional and leadership perceptions.ResultsA total of 39 mentees participated in the HOPA Mentorship Program between 2019 and 2025. Most mentees went on to serve on a HOPA committee (74%), with 28% serving in a leadership position on a committee. Most mentees (59%) also attended a HOPA-sponsored meeting following Mentorship Program participation. Mentees reported higher post-program ratings on leadership and professional development items compared with pre-program responses.ConclusionHOPA Mentorship Program participants demonstrated organizational contributions through committee service, leadership roles, and advocacy activities. Survey data demonstrated significant improvements in mentee self-reported leadership skills, career goal-setting, and professional engagement.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498404"},"PeriodicalIF":1.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model informed precision dosing for most accurate busulfan therapeutic drug monitoring.","authors":"Claudia Langebrake, Rick Admiraal","doi":"10.1177/10781552261489765","DOIUrl":"https://doi.org/10.1177/10781552261489765","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261489765"},"PeriodicalIF":1.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-related problems and pharmacist interventions within a pharmaceutical care programme in allogeneic haematopoietic stem cell transplantation.","authors":"Paula Guijarro-Martínez, María Ángeles Parro-Martín, Sagrario Martín-Aragón, Ana Álvarez-Díaz, Marina Sánchez-Cuervo","doi":"10.1177/10781552261498242","DOIUrl":"https://doi.org/10.1177/10781552261498242","url":null,"abstract":"<p><p>BackgroundPatients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) are exposed to highly complex pharmacotherapy, substantially increasing the risk of drug-related problems (DRPs).ObjectiveTo describe the frequency, causes and status of DRPs, as well as the clinical impact and acceptance of pharmacist interventions, within a structured pharmaceutical care programme in allo-HSCT patients.MethodsProspective, single-centre interventional study conducted within a pharmacist-led pharmaceutical care programme in adults undergoing allo-HSCT over a 12-month period (December 2023-December 2024), with follow-up to day +100 post-transplantation. DRPs and pharmacist interventions were classified using the Pharmaceutical Care Network Europe (PCNE) classification V9.1. Clinical impact was assessed using a validated scale adapted from Hatoum and colleagues.ResultsOf 41 patients assessed, 37 were included. A total of 289 DRPs were identified (median 8 DRPs per patient;IQR 6-11). Most DRPs involved treatment safety (60.2%) and effectiveness (26.6%). DRPs were most frequently identified during the in-hospital phase (45.7%) and post-discharge follow-up (37.0%). The main causes were drug selection (32.0%), dose selection (28.9%) and lack of clinical or analytical monitoring (27.2%). A total of 867 pharmacist interventions were performed; of 780 evaluated, 93.2% were accepted and 93.8% had a significant clinical impact. DRPs were totally (53.3%) or partially (31.1%) resolved.ConclusionA high burden of clinically relevant DRPs was identified in allo-HSCT patients. Pharmacist-led interventions were associated with high acceptance and significant clinical impact, supporting the integration of clinical pharmacists into multidisciplinary transplant teams. Prospective controlled studies are warranted to quantify the clinical benefit of pharmaceutical care in this setting.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498242"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to the editor concerning \"Development and internal validation of a clinical prediction model for 90-day clinically significant medication-related harm in adults initiating oral anticancer therapy: A multicenter prospective cohort study\".","authors":"Vivek Jayan, Sankiya M, Sudhakar S, Hana Zaiba Z, Aiswarya Lily Ray, Rakesh M","doi":"10.1177/10781552261498683","DOIUrl":"https://doi.org/10.1177/10781552261498683","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498683"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wastage of injectable anticancer drugs in a public hospital chemotherapy compounding unit: A prospective descriptive study.","authors":"Gabrielli De Lima Macedo, Ana Claudia De Almeida Ribeiro, André Teixeira Pontes","doi":"10.1177/10781552261497394","DOIUrl":"https://doi.org/10.1177/10781552261497394","url":null,"abstract":"<p><p>IntroductionEvidence on cancer drug wastage comes largely from high-income countries and generally excludes the pediatric setting. This study quantified consumption, leftover reuse and wastage in a chemotherapy compounding unit of the Brazilian public health system.MethodsProspective, observational, descriptive study covering every compounding episode performed between October and December 2024 in a public hospital serving adult oncology and adult and pediatric onco-hematology. Of 32 formulary injectable cytotoxic drugs, the 29 with activity were analyzed by quantity and cost. The daily balance was classified as reusable leftover or wastage by a 24-h stability threshold. Relative wastage (quantity discarded divided by quantity compounded) was calculated per drug.Results1298 patients were treated in 2030 compounding episodes. Compounded doses totaled 612,192 mg or IU (BRL 657,724.73), of which 5.5% by quantity came from reused leftovers. Wastage reached 53,996.45 mg or IU (BRL 30,391.78; USD 5206.84), equivalent to 8.8% of the compounded quantity, 4.6% of its value and 13.9 mg or IU per patient treated per month. Fluorouracil led both compounded quantity (29.5%) and wastage (27.1%), yet relative wastage was highest in low-volume drugs with short stability: fludarabine (158.9%), etoposide (134.0%) and azacitidine (95.5%). Pegaspargase, used predominantly in children, combined 57.5% relative wastage with the largest discard cost (BRL 15,402.00). Pertuzumab, the costliest drug compounded, generated none.ConclusionsWastage concentrated in drugs with short stability and vial sizes poorly matched to prescribed doses, whereas the greatest financial impact fell on high unit-cost biologics. Relative wastage reveals intervention targets that absolute volume does not.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261497394"},"PeriodicalIF":1.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}